Warren Sherman, an interventional cardiologist, is to join Cardio3 BioSciences SA as chief medical officer on 1 November to help the company develop its projects in the areas of regenerative medicine and cardiovascular disease. The Belgium-based company has an autologus cell therapy for heart failure in Phase 3 development.
Dr Sherman was most recently an interventional cardiologist at the Columbia University Medical Center in New York City and director of stem cell research and regenerative medicine at the Center for Interventional Vascular Therapy at Columbia. Dr Sherman received his bachelors’ degree from the Massachusetts Institute of Technology and his medical degree from the State University of New York.
Cardio3 BioSciences announced the appointment on 23 October
Copyright 2014 Evernow Publishing Ltd